PTC Therapeutics Inc
NASDAQ:PTCT
Relative Value
The Relative Value of one PTCT stock under the Base Case scenario is 51.15 USD. Compared to the current market price of 35.81 USD, PTC Therapeutics Inc is Undervalued by 30%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PTCT Competitors Multiples
PTC Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
PTC Therapeutics Inc
NASDAQ:PTCT
|
2.7B USD | 3 | -4.7 | -14.7 | -7.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 5.2 | 47.8 | 13.4 | 20.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
163.4B USD | 5.5 | 43.4 | 18.4 | 30.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 11.5 | 29.3 | 24.6 | 25.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 8.2 | 27.9 | 22.5 | 25 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.3 | 36.3 | 21.9 | 27.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.8B USD | 2.9 | 164.8 | 8.4 | 11.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.5B USD | 10.6 | -9.1 | -10.2 | -9.1 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 3.4 | 28 | 14.3 | 17.9 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |